United Therapeutics Corporation
UTHR
Classement en actions
#998
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Prix de l'action
$551.89
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$23.67B
Changement (1 jour)
1.61%
Changement (1 an)
30.61%
Pays
US
Échange United Therapeutics Corporation (UTHR)
Catégorie
Healthcare
Nombre d'actions en circulation pour United Therapeutics Corporation (UTHR)
Nombre d'actions en circulation au June 2026: 42.60M
Selon les derniers rapports financiers et le cours de l'action de United Therapeutics Corporation, le nombre actuel d'actions en circulation est de 42.60M. À la fin de December 2023, l'entreprise avait 46.80M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de United Therapeutics Corporation (UTHR) de 2000 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 42.60M | -5.75% |
| 2024 | 45.20M | -3.42% |
| 2023 | 46.80M | 2.86% |
| 2022 | 45.50M | 1.34% |
| 2021 | 44.90M | 1.58% |
| 2020 | 44.20M | 0.91% |
| 2019 | 43.80M | 0.69% |
| 2018 | 43.50M | -1.14% |
| 2017 | 44.00M | 0.46% |
| 2016 | 43.80M | -4.78% |
| 2015 | 46.00M | -4.52% |
| 2014 | 48.18M | -3.79% |
| 2013 | 50.08M | -3.87% |
| 2012 | 52.09M | -8.87% |
| 2011 | 57.16M | 1.82% |
| 2010 | 56.14M | 5.30% |
| 2009 | 53.31M | 16.40% |
| 2008 | 45.80M | 7.90% |
| 2007 | 42.45M | -7.76% |
| 2006 | 46.02M | 0.81% |
| 2005 | 45.65M | 5.06% |
| 2004 | 43.45M | 2.80% |
| 2003 | 42.27M | 2.37% |
| 2002 | 41.29M | 1.77% |
| 2001 | 40.57M | 5.45% |
| 2000 | 38.47M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | 496.01% |
US
|
|
| 396.00M | 829.58% |
US
|
|
| 478.91M | 1,024.21% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 45.98% |
NL
|
